Quarterly Earnings

WeRide, powered by RoboSense's advanced LiDAR, is rolling out 2,000 new Robotaxis, signaling a major shift from prototype to global mass deployment.

As electroCore preps its 2025 financial report, all eyes are on its product growth, the new Quell device, and its path to profitability in the booming bioelectronic market.

The data governance firm launches its new 'agentic' platform, aiming to free enterprises from 'pilot purgatory' by unifying data, AI, and compliance.

The clean energy firm reports strong Q1 revenue and eyes the data center market, but a shrinking backlog and wider gross loss present a mixed picture.

FinVolution Group is set to release its 2025 financials, with investors watching to see if international growth and AI tech can navigate market headwinds.

AIRO Group will present its future vision at a major tech conference, facing investor scrutiny amid ambitious growth plans and recent financial hurdles.

After a strategic overhaul, Aegis Brands reports a stunning Q4 profit, with its St. Louis chain's double-digit sales growth validating its new focused strategy.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

Americold holds its quarterly dividend steady at $0.23/share, signaling stability to investors while navigating industry headwinds with a new strategic plan.

Inuvo's stock faces uncertainty as a strategic pivot causes a steep Q4 revenue drop, betting its future on its privacy-focused IntentKey AI technology.

Automotive SaaS firm MotorK posts a dramatic financial turnaround, achieving positive cash flow in H2 2025 by leveraging AI and a bold customer strategy.

As Concentrix sets its Q1 earnings date, investors are watching closely to see if its AI-driven strategy can overcome market headwinds and cautious guidance.

The Bloomberg 500 adds 11 tech-heavy firms like Nebius Group and ASTS, signaling a major shift in market leadership driven by AI and digital infrastructure.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

The burger giant defied economic headwinds in 2025, posting record growth thanks to a key acquisition, new stores, and a focus on affordability.

German defense tech firm RENK Group reports a record €1.37B revenue, fueled by a 24% surge in its defense business amid global geopolitical tensions.

Record sales of its Trio® fertilizer fuel a major financial turnaround, as the company makes significant strides in extracting battery-grade lithium.

Ellington Credit reports a Q4 net loss amid a tough CLO market, yet management sees a major buying opportunity as asset prices get a reality check.